Skip to main content
. 2008 Apr 23;8:115. doi: 10.1186/1471-2407-8-115

Table 5.

Comparison of Response in HBsAg-positive patients treated with or without rituximab

Use of rituximab (N = 27) (33.3%) No rituximab (N = 54) (66.7%) p-value
Complete response 19 (70.4) 24(44.4) 0.16
Partial response 6 (22.2) 25(46.3)
Stable disease 1(3.7) 3(5.6)
Progressive disease 1(3.7) 2(3.7)